Navigation Links
New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
Date:5/8/2012

RIDGEFIELD, Conn., May 8, 2012 /PRNewswire/ -- Boehringer Ingelheim will present the latest data from its respiratory research pipeline at the Annual International Conference of the American Thoracic Society (ATS 2012), in San Francisco, CA, May 18 - 23. The 14 abstracts include results from a dose-ranging study evaluating tiotropium in subjects with moderate persistent asthma, additional analyses of data from the Phase II TOMORROW trial (To Improve Pulmonary Fibrosis with BIBF 1120), and results from a Phase II trial on the long-acting b2-agonist olodaterol in patients with COPD.

Boehringer Ingelheim's abstracts in respiratory research can be accessed through the ATS website, http://conference.thoracic.org. The Boehringer Ingelheim data will remain under embargo until the date and time that the data are presented (see details below). The ATS International Conference is one of the largest gatherings of pulmonary, critical care and sleep clinicians and researchers in the world, with 13 thousand attendees from 95 countries last year.

Collectively, these data underscore the company's focus on finding answers to the challenges faced by patients living with lung disease.

Tiotropium
Title Lead Author Presentation details Dose-Ranging Study Of

Tiotropium As Treatment

For Moderate Persistent

Asthma In Adolescents

C. Vogelberg

Scientific Abstract # 305

 

Date: Tuesday, May 22

Time: 8:15 a.m. – 10:45 a.m.

PDT / 11:15 a.m. – 1:45 p.m.

EDTBIBF 1120Title Lead Author Presentation details Treatment Of IPF With The

Tyrosine Kinase Inhibitor

BIBF 1120: Patient-

Reported Outcomes

In The TOMORROW Trial

K.K. Brown

Oral Presentation

 

Date: Monday, May 21

Time: 2:00 p.m – 4:30 p.m.

(data presented at 2:45 p.m.)

PDT / 5:00 p.m. – 7:30 p.m.

(data presented at 5:45 p.m.) EDTEfficacy of the Tyrosine

Kinase Inhibitor BIBF 1120

in Patients with IPF:

Consistent Pattern of

Primary Endpoint Results

in Sensitivity Analyses of

the TOMORROW trial

L. Richeldi

Oral Presentation

 

Date: Monday, May 21

Time: 2:00 p.m – 4:30 p.m.

(data presented at 2:30 p.m.)

PDT / 5:00 p.m. – 7:30 p.m.

(data presented at 5:30 p.m.) EDTOlodaterolTitleLead Author Presentation details Comparison Of 24-Hour

FEV1 Profile For Once-

Daily Versus Twice-Daily

Treatment With

Olodaterol, A Novel Long-

Acting b2-Agonist, In

Patients With COPD

G. Joos

Thematic Poster # D60

 

Date: Monday, May 21

Time: 10:45 a.m – 12:30 p.m.

PDT / 1:45 p.m. – 3:30 p.m.

EDTLung FunctionTitleLead Author Presentation details Lung Function And

Exercise Impairment In

Patients With GOLD Stage

I And II COPD

D. E. O'Donnell

Thematic Poster  # G74

 

Date: Wednesday, May 23

Time: 8:15 a.m. – 4:30 p.m.

PDT / 11:15 a.m. – 7:30 p.m. EDT

Poster Discussion from

10:45 a.m. – 12:30 p.m. PDT /

1:45 p.m. – 3:30 p.m. EDTBoehringer Ingelheim: Leading respiratory forwardTreatment of respiratory diseases has been a major area of focus for Boehringer Ingelheim for more than 90 years and significant resources are dedicated to research in this field. In addition to new possible treatment options for COPD, Boehringer Ingelheim has also branched out into developing treatment options for other airway diseases, including asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.


'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2020)... LOS ANGELES (PRWEB) , ... March 27, 2020 ... ... exclusivity, and luxurious lifestyle, is privileged to present Dr. Timothy Katzen as a ... addition to the Haute Living partnership. , Haute Beauty offers a prominent collective ...
(Date:3/20/2020)... ... March 20, 2020 , ... Users who have tested positive for COVID-19 can ... database of detailed location information, such as a specific building on campus or a ... to the virus. The app will also help people to more easily recall where ...
(Date:3/19/2020)... , ... March 19, 2020 , ... ... as safe and effective as single food immunotherapy, according to research scheduled for ... Meeting before it was cancelled due to the situation with coronavirus disease 2019 ...
Breaking Medicine Technology:
(Date:3/22/2020)... ... March 21, 2020 , ... In partnership with UC ... honor our community’s medical professionals and first responders. The title comes from the English ... the city and its flag. , Proceeds from the sale of the shirt ...
(Date:3/22/2020)... ... ... “At a time when the public is being told not to visit ... First Stop Health Telemedicine program is a valuable resource to fall back on. ... a valuable tool that can help Americans in their fight to stay healthy,” began ...
(Date:3/20/2020)... ... 20, 2020 , ... My heart goes out to those across our nation ... a loved one recently through similar circumstances - underlying conditions compounded by a virus ... a gamut of negative emotions just like many have: fear, anxiety, uncertainty. In contrast, ...
(Date:3/20/2020)... , ... March 20, 2020 , ... ... together an interdisciplinary team of researchers in machine learning, bioinformatics, immunology, virology and ... current and future outbreaks. , "The COVID-19 crisis gives us an opportunity and ...
(Date:3/19/2020)... ... March 19, 2020 , ... Therapies of The Rockies has Colorado’s back, ... crisis. TOTR welcome new telepractice patients across the country, as remote therapy services have ... to begin or resume your services safely! , Therapies of The Rockies is a ...
Breaking Medicine News(10 mins):